Mapping the humoral immune response to the surface glycoproteins of the mumps virus
Active Grant Awarded
- Award ID
- R21AI196816
- Recipient
-
La Jolla Institute For Immunology UEI ZPAUY3FQMM26
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $279,000
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 26% complete
- Place of performance
- La Jolla, CA 92037, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services' National Institutes of Health, through its National Institute of Allergy and Infectious Diseases, awarded La Jolla Institute For Immunology a $279,000 grant on May 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The full $279,000 is obligated, and the period of performance ends April 30, 2028, with work performed in La Jolla, CA 92037.
The recipient will develop panels of human monoclonal antibodies against the mumps virus HN and F surface glycoproteins, sourced from both vaccinated and convalescent individuals. The work maps which antibodies and epitope target sites produce the broadest viral genotype recognition, particularly across vaccine-derived genotype A and currently circulating genotype G. The project also produces the monoclonal antibodies themselves, providing a basis for post-exposure treatments and guidance on booster development.
The project addresses ongoing mumps outbreaks among young adults, including vaccinated individuals, and the source identifies protection against mumps as the least effective component of the MMR vaccine.
Description
- Abstract
- Mumps virus is one component of the MMR vaccine, which has been successful in the global effort against measles, mumps and rubella. However, of the three viruses, protection against mumps is the least effective. Cycles of mumps virus outbreaks continue to occur, especially among young adults and even in the vaccinated. 10% of patients in a recent SAN diego county outbreak were hospitalized. Breakthrough infections could be linked to sequence differences between the vaccine strain and the newly emerged mumps genotype G. Surprisingly, although we have had this vaccine since 1971, medical science still does not know what the human antibody response is against mumps virus, from either vaccination or natural infection. No human antibodies against mumps have been yet described, and no structures of any antibodies against mumps have yet been determined. Thus, we are lacking understanding of which antibodies and which epitope target sites on the surface proteins HN and F are most effective, and we are lacking the antibodies themselves which might be incorporated into post-exposure treatments. In this program, we will develop panels of human monoclonal antibodies against mumps HN and F from both vaccinated and convalescent individuals. Results obtained from this program will illuminate what humans target in their immune responses, and which target sites, or epitopes, lead to broadest viral genotype recognition, especially between vaccine-derived genotype a and currently circulating genotype G of the virus. The results of this program will also provide the essential mabs themselves from which we may develop post-exposure treatments and guide development of boosters.
Quick answers
Who received award R21AI196816?
R21AI196816 was awarded to La Jolla Institute For Immunology by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on May 19, 2026.
How much is award R21AI196816 worth?
$279,000 has been obligated on R21AI196816.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award